NAD+ & sirtuin signaling

One of 6 mechanistic pathways to ⏳ Longevity & healthspan · 13 options

NAD+ falls by roughly half between young adulthood and old age. It is the obligate cofactor for the sirtuins that regulate DNA repair, mitochondrial biogenesis and inflammation. The precursors reliably raise the pool — the honest gap is what that buys you clinically.

🩸 Is this pathway actually your problem?

NAD+ itself isn't routinely measurable, so this is indirect. Worth knowing: heavy precursor dosing consumes methyl groups, so watch homocysteine if you are running NMN or NR at scale.

hs-CRP (High-Sensitivity C-Reactive Protein)HbA1c (Hemoglobin A1c)HomocysteineComprehensive Metabolic Panel (CMP)

⏳ Longevity Baseline covers these in one panel →

What engages this pathway

Ordered by how directly each one acts on the mechanism above — never by how much trial evidence exists. Each links to its full breakdown with dosing, half-life and vendor.

💉 Nad+

Direct IV NAD+. Whether intact NAD+ crosses the cell membrane is genuinely contested — much of it is likely degraded to precursors first, which would make the expensive infusion an inefficient way to deliver NR.

🧪 Theoretical / mechanistic

💉 NR

The best-characterized precursor with the most human pharmacokinetic work. Raises NAD+ dependably. Clinical endpoints have been consistently underwhelming, which is worth sitting with rather than skipping past.

✅ Clinically validated

💉 5-Amino-1MQ

NNMT inhibition preserves the existing nicotinamide pool rather than adding precursor — a different and arguably smarter lever on the same system.

🧪 Theoretical / mechanistic

🧬 NMN

Oral NMN. Raises the NAD+ pool in human trials; whether a raised pool translates into anything you can feel remains the open question for the whole category.

🧪 Theoretical / mechanistic

🧬 NR (Nicotinamide Riboside)

NiaCel — the NR material with the most human pharmacokinetic data behind it. The pool rises reliably; the clinical endpoints have been modest.

✅ Clinically validated

🧬 ResveraCel

NR plus resveratrol plus TMG — precursor, proposed sirtuin activator and methyl donor. The TMG is there because heavy NAD+ precursor dosing consumes methyl groups, which is a real and often-ignored issue.

🧪 Theoretical / mechanistic

🧬 Niacinamide

The cheapest NAD+ precursor. It also inhibits sirtuins at high concentration, which is an awkward and under-discussed contradiction in the longevity case for it.

✅ Clinically validated

🧬 Resveratrol

The original proposed sirtuin activator. The direct SIRT1 activation finding was challenged as a fluorescent-assay artifact, and human trials have largely disappointed. Honest position: the story was better than the data.

📊 Correlative

🧬 Pterostilbene

Methylated resveratrol with far better bioavailability and a longer half-life. Inherits the mechanism and the uncertainty.

🧪 Theoretical / mechanistic

🧬 Tocotrienols

Beyond antioxidant activity, delta-tocotrienol has senolytic-adjacent effects in preclinical work and human cholesterol data.

✅ Clinically validated

🧬 Cycloastragenol

The astragalus-derived telomerase activator behind TA-65. It does activate telomerase in cell culture — the open question is whether lengthening telomeres in a somatic cell is desirable, since it is also what a cancer cell needs to become immortal. Genuinely double-edged, and rarely presented that way.

🧪 Theoretical / mechanistic⚠ Safety flag

🧬 Gynostemma

Jiaogulan contains gypenosides structurally similar to ginseng's, and it activates AMPK in cell work. Traditional use in Chinese longevity villages is the origin of the interest.

🧪 Theoretical / mechanistic

🧬 Moringa

Dense polyphenol and micronutrient profile with isothiocyanates related to sulforaphane's. Nutritionally impressive; the longevity claim is extrapolated from its constituents.

📊 Correlative
Nothing here is ranked by evidence tier. A lot of what works in this space has never had the trial run, and sorting by trial count would bury exactly the compounds you came looking for. The tier is a label. The mechanism is the map.

What actually decides this outcome, in order of size

This page has a premise, a mechanism and a set of products, and in 2026 the premise acquired a serious problem. Ranked by how much of the outcome each one owns:

  1. Whether the pool actually falls with age, which is the sentence this entire category is built on. Human whole-blood NAD+ levels were reported not to vary with age or with lifestyle interventions Tretowicz 2026. That is one paper, in one compartment, and blood is not muscle or brain. It is also a direct challenge to the premise, and a page that lists thirteen products for restoring a decline owes the reader the existence of a study reporting there was no decline to restore in the compartment that was measured.
  2. Whether the precursor raises the pool, which is the one thing here that is not in dispute. Chronic nicotinamide riboside supplementation was well tolerated and elevated NAD+ in healthy adults Martens 2018. The pharmacology works. That is a different claim from the clinical one and the gap between them is the whole page.
  3. What happened when the raised pool met a clinical endpoint. A randomized phase 1 trial in Parkinson disease reported on supplementation directly Brakedal 2022, and a high-dose safety trial followed Berven 2023. In the mouse intervention testing program, nicotinamide riboside was tested alongside another compound and the lifespan result is what it is Harrison 2021. Read those before the marketing rather than after it.
  4. Whether adding precursor is even the smartest lever, because two alternatives act on consumption rather than supply. The flavone apigenin inhibits CD38, with implications for cellular NAD+ metabolism Escande 2013, and inhibiting nicotinamide N-methyltransferase preserves the nicotinamide already in the salvage pathway. That enzyme regulates hepatic nutrient metabolism through SIRT1 protein stability Hong 2015, its knockdown protected against diet-induced obesity in mice Kraus 2014, and turnover inhibitors have been characterized Akerud 2025. All of that is preclinical and it is a genuinely different strategy.
  5. The methyl cost, which is the most under-discussed practical issue on the page. Excess nicotinamide is cleared by methylation, so heavy precursor dosing consumes methyl groups. That is why a product on this page includes trimethylglycine, and it is why Homocysteine is the cheapest honest read-out here. Whether sustained high-dose loading raises homocysteine in practice is a prediction from the enzymology rather than a published trial result, and it is labeled as one.
  6. Whether the sirtuin activator half survived scrutiny, which it largely did not. The direct activation finding for resveratrol was challenged as an assay artifact, and human metabolic trials have disappointed. Meanwhile the telomerase claim attached to Cycloastragenol has cell-line evidence and a published correction in the record Al-Dulaimi 2025 Al-Dulaimi 2025, and the capability it describes is the one a transformed cell needs.

The order to run these in, and what has to be true first

Read the premise problem first, then decide whether you are buying a pharmacology or a hypothesis. The ordering below is honest about which of the two each item is.

  1. Start by deciding what would change your mind. If the answer is nothing, this page is a purchase rather than an experiment. The premise paper Tretowicz 2026 and the human pharmacokinetic paper Martens 2018 between them define the space: the pool may not fall, and it can certainly be raised.
  2. Baseline bloods before any loading. Homocysteine with Folate, RBC and Vitamin B12, Comprehensive Metabolic Panel (CMP), Lipid Panel (Cholesterol, HDL, LDL, Triglycerides), hs-CRP (High-Sensitivity C-Reactive Protein) and Uric Acid. The methyl panel is here because it is the one thing on this page that a precursor is known to consume.
  3. NR or NR (Nicotinamide Riboside) if you want the best-characterized pharmacology. It raises the pool dependably in humans Martens 2018, the clinical endpoints have been modest Brakedal 2022, and a high-dose safety trial exists Berven 2023. Buying it as a pharmacology with an open clinical question is defensible; buying it as an established anti-aging intervention is not.
  4. NMN is the same argument with less human pharmacokinetic work behind it. It raises the pool in human trials and whether that translates is the open question for the whole category.
  5. Niacinamide is the cheapest precursor and carries a contradiction worth stating. It feeds the salvage pathway and at high concentration it inhibits sirtuins, which is awkward for a page named after them and is rarely mentioned on the label.
  6. ResveraCel exists because of the methyl-group problem. Precursor plus a proposed activator plus a methyl donor. The methyl donor is the part with a mechanistic reason to be there; the activator is the part whose story outran its data.
  7. 5-Amino-1MQ is the consumption-side lever and it is mouse-stage. The enzyme it targets regulates hepatic metabolism through SIRT1 stability Hong 2015, knockdown protected against diet-induced obesity in mice Kraus 2014, and inhibitor turnover has been characterized Akerud 2025. No human trial has reported, and saying so is the whole entry.
  8. Nad+ by infusion is the most expensive and least defensible route. Whether intact NAD+ crosses the cell membrane is contested, and much of an infusion is likely degraded to precursors first, which would make it a costly way to deliver something oral. Gynostemma, Moringa and Cycloastragenol are the traditional end, and the last of those carries the telomerase double edge Al-Dulaimi 2025 Al-Dulaimi 2025.

What gets bought for this that cannot move it

The category that fails structurally is the precursor bought to correct a decline that may not exist in the compartment being measured. Human whole-blood NAD+ was reported not to vary with age or lifestyle interventions Tretowicz 2026. Whole blood is not muscle, liver or brain, and tissue-level decline may still be real. But the graph everybody sells against is a blood graph, and one careful study now says that graph is flat. That is the honest state of the premise as of 2026 and it belongs on the page rather than in a footnote.

The surrogate here is the pool itself, and it is a perfect specimen. The precursors raise it reliably in humans Martens 2018, which makes them easy to sell and easy to feel good about. The clinical endpoints have been consistently underwhelming Brakedal 2022, and the mouse lifespan program result is public Harrison 2021. A raised pool is a demonstration that the pharmacology works. It is not a demonstration that the pharmacology matters, and the entire category is priced on the second.

Two practical failures. Heavy precursor loading consumes methyl groups, which is a mechanistic prediction with a cheap test attached and almost nobody runs it. And Urolithin A is on the neighboring pathway rather than here for a reason: it is a mitophagy argument, its production from ellagitannins depends on a gut microbial phenotype that not everybody has Tomas-Barberan 2014, and conflating it with NAD chemistry is a category error.

If the goal underneath is different, so is the page. If the target is nutrient sensing rather than cofactor supply, Nutrient sensing — mTOR, AMPK & caloric restriction mimetics. If it is mitochondrial quality, Autophagy & mitochondrial quality control. If it is fatigue with a cause, Mitochondrial ATP production is the page and an alpha-ketoglutarate formulation with a human report on biological age measures Demidenko 2021 is a different claim again. And intravenous NAD is an unlicensed infusion, which is a clinical decision rather than a supplement one.

How you would know it was working, on a real read-out and a real timescale

This page makes two predictions. Homocysteine is the read-out that responds to heavy precursor loading, because clearance of excess nicotinamide is a methylation reaction, and it is the one number here nobody checks; and no product on this page will change hs-CRP (High-Sensitivity C-Reactive Protein), Lipid Panel (Cholesterol, HDL, LDL, Triglycerides) or HbA1c (Hemoglobin A1c) in a healthy adult, which is worth confirming rather than assuming because it is what the clinical trials have mostly found Brakedal 2022.

  • Homocysteine with Folate, RBC and Vitamin B12 at baseline and 12 weeks on any sustained precursor dose. Twelve weeks because red cell folate integrates over months and because a methyl-group drain, if it happens, is cumulative rather than acute.
  • Comprehensive Metabolic Panel (CMP) and Lipid Panel (Cholesterol, HDL, LDL, Triglycerides) at baseline and 12 weeks. Transaminases because these are daily long-term products, and lipids because niacin-family compounds have historically moved them; nicotinamide does not flush and is not niacin, which is a difference worth knowing before a dose is chosen.
  • Uric Acid at baseline and 12 weeks. High-dose nicotinamide compounds can affect urate handling, and it is cheap enough to be worth having beside the rest.
  • hs-CRP (High-Sensitivity C-Reactive Protein) and HbA1c (Hemoglobin A1c) at baseline and 6 months, as falsification rather than as targets. If the sirtuin story is doing anything systemic in a healthy adult, this is roughly where it would show, and the honest expectation is that it will not Harrison 2021.
  • A fixed physical test, monthly, if you are running this for function. Grip strength or a timed walk. It is free, it is the endpoint the category implies, and it is more informative than any pool measurement a consumer can buy.

What will fool you. Direct NAD+ measurement in blood is technically demanding, the sample degrades quickly, and a commercial result should be treated with the same caution the premise paper implies Tretowicz 2026. Feeling better on an infusion is an infusion experience, which includes fluid, time lying down and expectation. Apigenin acts on this system through CD38 rather than as a precursor Escande 2013, so a combination product may be working through a route the label does not mention. Nicotinamide inhibits sirtuins at high concentration, which is the opposite of the page's premise. And a correction notice attached to a telomerase paper is part of that paper's record Al-Dulaimi 2025.

Sources read for these sections

The other 5 routes to longevity & healthspan

Pick the pathway that matches where you are actually stuck. An appetite drug does nothing for someone who already undereats.

Nutrient sensing — mTOR, AMPK & caloric restriction mimetics13 optionsCellular senescence & senolytics7 optionsAutophagy & mitochondrial quality control10 optionsGlycation, oxidation & protein damage17 optionsThe unglamorous evidence — what actually has mortality data14 options

You know the goal. Skool has the plan.

This pathway is one arm of The Longevity & healthspan Blueprint. The members' version has where this arm sits in the sequence, what to stack it with, and the markers that tell you to keep going or stop.

Open The Longevity & healthspan Blueprint in Skool →

$10/mo, cancel anytime.

← Open this pathway in the interactive Vault

Frequently asked questions

What is the nad+ & sirtuin signaling pathway for longevity & healthspan?

NAD+ falls by roughly half between young adulthood and old age. It is the obligate cofactor for the sirtuins that regulate DNA repair, mitochondrial biogenesis and inflammation. The precursors reliably raise the pool — the honest gap is what that buys you clinically.

What compounds and supplements work through nad+ & sirtuin signaling?

13 options are mapped to this pathway in the Vault, including Nad+, NR, 5-Amino-1MQ, NMN. They are grouped by the mechanism they act through rather than ranked by how much trial evidence exists — 4 carry clinical validation and 7 are mechanistic predictions.

How do I know if nad+ & sirtuin signaling is actually my problem?

NAD+ itself isn't routinely measurable, so this is indirect. Worth knowing: heavy precursor dosing consumes methyl groups, so watch homocysteine if you are running NMN or NR at scale. The markers worth checking are hs-CRP (High-Sensitivity C-Reactive Protein), HbA1c (Hemoglobin A1c), Homocysteine, Comprehensive Metabolic Panel (CMP).

Are the 7 theoretical options for nad+ & sirtuin signaling worth considering?

Unproven is not the same as ineffective. Of the 13 options on this pathway, 4 have clinical validation and 7 are graded theoretical — meaning the mechanism is sound but the specific human trial has not been run, which is true of a great deal of what works in this space. Nothing on this page is ordered by evidence tier, because sorting by trial count would bury the compounds you came looking for.

Where this goes next

Test itLongevity BaselineThe panel that says whether this is your problemGo deeperThe Longevity BlueprintThe free week-by-week structure behind this goal
The full protocol$10/mo

Everything above is the free case for NAD+ & sirtuin signaling. The protocol — the dosing, the order to correct things in, the week-by-week schedule and what to retest — is a lesson inside Skool.

The Longevity Blueprint
Educational and research reference only — not medical advice, and not a recommendation for human use. Mechanistic predictions are exactly that: what the biology suggests should happen, which is not the same as what has been shown to happen.

↑ Back to on this page

The blueprint this pathway sits insideThe Longevity Blueprint →The full 24-week stack this pathway belongs to — every arm, the sequence, and the bloodwork.